BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant (IPG695)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 26 May 2021
Idiopathic pulmonary fibrosis in adults (QS79)Product type:Quality standardPublished: 29 January 2015
Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)Product type:GuidanceProgramme:Clinical guidelineLast updated: 23 May 2017Published: 12 June 2013
Imbio CT lung texture analysis for identifying interstitial lung disease (MT618) (MIB272)Status:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lung texture analysis for measuring interstitial lung diseases (MIB272)Product type:AdviceProgramme:Medtech innovation briefingPublished: 10 August 2021
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nintedanib for treating idiopathic pulmonary fibrosis (TA379)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (TA864)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2023
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 November 2021
Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 February 2018
Pulmonary sarcoidosis: infliximab (ES2)Product type:AdviceProgramme:Evidence summaryPublished: 20 December 2016
Refractory extrapulmonary sarcoidosis: infliximab (ES4)Product type:AdviceProgramme:Evidence summaryPublished: 17 January 2017